Search research articles
Contact Us
Filters
Showing results (351-360 of 442) with videos related to
Page
of 45
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic
Denis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Cancer Discovery
|
October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S Hong, Van K Morris, Badi El Osta, et al.
Journal of Immunotherapy and Precision Oncology
|
November 11, 2024
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma
Mohamed A Gouda, Bettzy Stephen, Yanyan Tian, et al.
Gynecologic Oncology
|
November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer
Shannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
Cancer Immunology Research
|
September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype
Ashvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
Chad Tang, James W Welsh, Patricia de Groot, et al.
JCO Precision Oncology
|
August 11, 2018
Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in <i>KIT</i>-Mutant Melanoma
Junna Oba, Sun-Hee Kim, Wei-Lien Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
Kai He, David Berz, Shirish M Gadgeel, et al.
Cancer
|
April 23, 2014
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
David S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, et al.
Page
of 45
Search research articles
Search
Showing results (351-360 of 442) with videos related to
Sort By:
Page
of 45
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic
Denis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Cancer Discovery
|
October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S Hong, Van K Morris, Badi El Osta, et al.
Journal of Immunotherapy and Precision Oncology
|
November 11, 2024
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma
Mohamed A Gouda, Bettzy Stephen, Yanyan Tian, et al.
Gynecologic Oncology
|
November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer
Shannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
Cancer Immunology Research
|
September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype
Ashvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
Chad Tang, James W Welsh, Patricia de Groot, et al.
JCO Precision Oncology
|
August 11, 2018
Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in <i>KIT</i>-Mutant Melanoma
Junna Oba, Sun-Hee Kim, Wei-Lien Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
Kai He, David Berz, Shirish M Gadgeel, et al.
Cancer
|
April 23, 2014
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
David S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, et al.
Page
of 45